As a derivative of 3,4-methylenedioxy-β-nitrostyrene, HPW-RX40 can not only inhibit integrin from preventing platelet aggregation but also inhibit the activation of the integrin β1/FAK/paxillin signaling pathway from enhancing the sensitivity of breast cancer cells to anoikis [128,129]. Here, PTK2 is linked to breast carcinoma.